BioInvent Q2 2024: Positive Development with BI-1206 and BI-1808 - Redeye
Redeye comments on BioInvent's Q2 report 2024. Positive new results from BI-1206 in lymphoma and solid tumours and from BI-1808 were presented during the quarter.
ANNONS
Redeye comments on BioInvent's Q2 report 2024. Positive new results from BI-1206 in lymphoma and solid tumours and from BI-1808 were presented during the quarter.